This trial is evaluating whether Low Dose MT-1303 will improve 1 primary outcome and 3 secondary outcomes in patients with Colitis. Measurement will happen over the course of Baseline to Day 85.
This trial requires 336 total participants across 3 different treatment groups
This trial involves 3 different treatments. Low Dose MT-1303 is the primary treatment being studied. Participants will be divided into 2 treatment groups. Some patients will receive a placebo treatment. The treatments being tested are in Phase 2 and have already been tested with other people.
"We found mt-1303 to be effective in this study and was typically considered safe and well tolerated as part of the induction, maintenance, and stabilization of disease." - Anonymous Online Contributor
"Around 5.7 million people in the United States have at least one severe episode of UC or CD a year. UC was the more common of the two diseases." - Anonymous Online Contributor
"This is the largest study examining treatments of the inflammatory bowel disorders, and may have important implications for clinicians. For patients with Crohn's disease, common treatments include medical therapy with anti-TNF agents (mainly infliximab), and surgical procedures, whereas for UC patients, these options are common. The utility to physicians and patients of the use of alternative remedies is unknown." - Anonymous Online Contributor
"Colitis, ulcerative is a chronic immune-motile disease. This disease is not curable but this can usually be controlled by the patient's lifestyle changes and medications." - Anonymous Online Contributor
"Colitis is characterized by symptoms such as bloody diarrhea, vomiting, abdominal pain, or weight loss. Most patients have signs of colitis such as diarrhea and abdominal pain that persist for less than two weeks and then disappear. Signs of celiac disease include skin flushing, weight loss, low-grade malabsorption, and diarrhea that lasts for more than a month. In celiac disease, if diarrhea persists, it is called IBS-D or irritable bowel syndrome with diarrhea. In ileal CD, there are signs and symptoms similar to colitis, such as diarrhea and abdominal pain. In children with CD, changes in growth, weight loss, and anemia can also imply a more severe form of CD." - Anonymous Online Contributor
"The same factors that increase the risk of IBD can cause colitis, and vice versa. This means that people with both ulcerative colitis and Crohn's disease have more than one factor causing inflammation." - Anonymous Online Contributor
"Ulcerative colitis is a chronic inflammatory disease of the bowel that predominantly affects the colon. Symptoms vary depending on which part of the colon is affected. The disease is caused by an altered microbiota. Most cases are asymptomatic. It is strongly associated with inflammatory bowel disease (IBD) where many different autoimmune and infectious proteins are involved as cause or a synergistic effect. The disease is more common in females than males, and can also occur in adolescents." - Anonymous Online Contributor
"Given the high cost and minimal safety of low dose mt-1303, it is surprising that only a small number of patients had the treatment extended to week 12. If low dose mt-1303 is ineffective in these patients, low dose mt-1303 should not be used for IBD." - Anonymous Online Contributor
"These are commonly seen primary causes of colitis secondary, which may involve any of the immunologic disorders. The most frequent cause of primary colonic disorders is a colonic neoplasm or fecal stricture(s. Most common sites of colorectal neoplasms include the right colon and sigmoid colon on an average. In primary colonic neoplasms, the most common sites of disease spread are to peritoneal or thoracic regions, followed by the ileocecal colon Region and then lymph node metastatic patterns. There also appears to be a high incidence of rectovulum neoplasm." - Anonymous Online Contributor
"We found no evidence for mt-1303 as an effective anti-tumor drug. A thorough review of the available literature as well as additional validation of the findings in this report will be useful for the implementation of this novel compound in a clinical trial." - Anonymous Online Contributor
"Currently available results suggest that low dose mt-1303 may have an antimetabolite or antimetabolite prodrug action to affect intestinal inflammatory and healing processes. The clinical use of mt-1303 remains in its infancy, but it is not without potential." - Anonymous Online Contributor
"Findings from a recent study of this study demonstrated no significant difference in effectiveness of low dosage mt-1303 in comparison to placebo-controlled group. However, this did not necessarily mean that low dosage mt-1303 is less effective than the conventional dosage. To determine which dosage is more effective, larger studies are needed with adequate statistical power." - Anonymous Online Contributor